We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $1.11B
1-Year Est. Return 866.76%
This Fund
S&P 500
This Quarter Est. Return
+40.16%
1 Year Est. Return
+866.76%
3 Year Est. Return
+2,969.39%
5 Year Est. Return
+5,038.91%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$209M
Cap. Flow
-$52.4M
Cap. Flow %
-4.71%
Top 10 Hldgs %
78.54%
Holding
34
New
5
Increased
4
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$35.8M
2
SMMT icon
Summit Therapeutics
SMMT
+$22.2M
3
DFTX
Definium Therapeutics
DFTX
+$12.6M
4
ANL
Adlai Nortye Group ADS
ANL
+$11.4M
5
PHVS icon
Pharvaris
PHVS
+$8.83M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$29.8M
2
KALV
KalVista Pharmaceuticals
KALV
+$29.2M
3
TERN
Terns Pharmaceuticals
TERN
+$27.9M
4
TRVI icon
Trevi Therapeutics
TRVI
+$17M
5
OCUL icon
Ocular Therapeutix
OCUL
+$9.89M

Sector Composition

Rank Sector Weight
1 Healthcare 97.93%
2 Miscellaneous 2.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTX icon
26
Context Therapeutics
CNTX
$33.2M
$1.69M 0.15%
3,050,000
-2,200,000
-42% -$4.46M
GOSS icon
27
Gossamer Bio
GOSS
$85.7M
$1.28M 0.11%
7,750,000
– –
CATX icon
28
Perspective Therapeutics
CATX
$357M
– –
-791,555
Closed -$3.3M
CNTA
29
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-750,000
Closed -$29.8M
KALV
30
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,450,000
Closed -$29.2M
LXEO icon
31
Lexeo Therapeutics
LXEO
$401M
– –
-1,100,000
Closed -$6.31M
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
– –
-530,000
Closed -$27.9M
BBOT
33
BridgeBio Oncology
BBOT
$720M
– –
-719,000
Closed -$6.44M
EVMN
34
Evommune Inc
EVMN
$445M
– –
-143,472
Closed -$3.3M
1
2

Similar funds

OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $1.11B AUM
JWM
JGP Wealth Management Bend, Oregon $1.11B AUM 35.22% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.11B AUM 12.31% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
AF
Arrow Financial Glens Falls, New York $1.12B AUM 24.16% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
VFM
Viking Fund Management Minot, North Dakota $1.12B AUM 44.65% 1-Year Est. Return

Octagon Capital Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Octagon Capital Advisors held 34 positions worth $1.11B, up 23% from $904M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Octagon Capital Advisors withdrew a net $52.4M in Q2 2026, closing 7 positions and reducing 6 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $29.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Octagon Capital Advisors opened a new position in Summit Therapeutics worth $18.2M.

  • Octagon Capital Advisors's largest Q2 2026 buy was Summit Therapeutics: 1,250,000 shares worth $18.2M.
  • Octagon Capital Advisors added most to Abivax in Q2 2026, an estimated $35.8M increase.
  • Octagon Capital Advisors's biggest Q2 2026 reduction was Trevi Therapeutics, cutting an estimated $17M.
  • Octagon Capital Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $29.8M.
  • Octagon Capital Advisors's ten largest holdings make up 79% of its $1.11B portfolio in Q2 2026.
  • Octagon Capital Advisors opened 5 new positions and closed 7 in Q2 2026.
  • Octagon Capital Advisors's portfolio value rose 23% quarter-over-quarter to $1.11B.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.